Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated, when compared with placebo. Median nebulization times were less than four minutes for both doses in the study. Initial review of the data has not identified any serious adverse events attributed to study drug. Patients continue to be treated in a 52-week safety study to collect long-term safety data on the two doses under investigation.

"Based on our initial review of these data, both the placebo and study groups experienced improvements in asthma symptoms, but the differences were not statistically significant. We observed a higher than expected response in the placebo group, starting as early as one week after randomization and continuing throughout the 12 week treatment period," said Timothy S. Nelson, Chief Executive Officer of MAP Pharmaceuticals. "We and our partner, AstraZeneca, are conducting further analyses of these data to determine appropriate next steps going forward for the program. The Company remains dedicated to developing therapies for children suffering from asthma."

About the AstraZeneca Collaboration

MAP Pharmaceuticals and AstraZeneca have a collaboration agreement to develop and commercialize UDB in the United States, and AstraZeneca has rights to develop and commercialize UDB outside of the United States.

About the Study

In this randomized, double-blind, placebo-controlled study, 360
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Oxis International, Inc. ... , the election of Anthony J. Cataldo as ... Effective November 19, 2014, Ken Eaton ... the Board of Directors of Oxis International, Inc. to pursue ... has been named Chief Executive Officer of Oxis International, Inc. ...
(Date:11/21/2014)... 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... offering of $80,000,000 aggregate principal amount of 5.25% Convertible ... private offering within the United States ... buyers pursuant to Rule 144A under the Securities Act ... also granted the initial purchasers an option to purchase ...
(Date:11/18/2014)... ANGELES , Nov. 18, 2014  Sanguine ... development, patient engagement and study recruitment – will ... called Sangre, to help Pfizer Inc. find and ... (CIP) and their family members to participate in ... potentially identify DNA mutations and hopefully aid in ...
Breaking Medicine Technology:OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
... , KNOXVILLE, Tenn., Dec. 2 ... nation,s largest provider of hospital-based clinical outsourcing, announced it ... two groups in South Carolina and Illinois. , An ... S.C., will allow TeamHealth Teleradiology to provide services for ...
... , WALTHAM, Mass. and NEW YORK, Dec. ... and NYU Langone Medical Center announced findings from a study ... osteoarthritis have been published this week in the "Online First" ... at http://ard.bmj.com/cgi/rapidpdf/ard.2009.113043v1.pdf . Results from ...
Cached Medicine Technology:TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois 2Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 2Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 3Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 4
(Date:11/22/2014)... New York (PRWEB) November 22, 2014 ... on behalf of patients who allegedly developed Type 2 ... in the federal multidistrict litigation now underway in U.S. ... reports. According to court documents, the litigation will convene ... a.m. The Court has directed Lead Counsel for Plaintiffs ...
(Date:11/22/2014)... UWDress.com is gratified to introduce its new collection of ... company has also offered an attracting discount on these ... of wedding dresses, UWDress.com is good at manufacturing all ... gowns are provided over 20 colors, which have diverse ... famous for high quality. Therefore, its sales increased quickly ...
(Date:11/22/2014)... November 22, 2014 Sandbridge Capital, ... investments in the consumer brand sector, acquired a ... will be used to help fund BackJoy’s global ... rollout, particularly its proprietary apparel and footwear lines. ... BackJoy’s Board of Directors. , BackJoy is a ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as part ... the latest and coolest technology products available to consumers. ... conducted the product review and shared with viewers how ... , From pollution to hazardous substances in water, harmful ... to remove these chemicals, especially in water. , A ...
(Date:11/22/2014)... 2014 (HealthDay News) -- A clinical trial of hydroxyurea ... halted a year early because the results show it ... disease and reduce the risk of stroke. The ... medical centers in the United States and Canada, was ... and Blood Institute (NHLBI). Researchers compared monthly blood ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2
... loss, expert says , MONDAY, March 22 (HealthDay News) ... people with mild cognitive impairment, the stage before Alzheimer,s ... that we need to pay attention to this time ... starting to have problems forgetting things," study author Robert ...
... Infertile men ... the average man according to a new study published in the journal, Cancer. , ... San Francisco, Calif. (Vocus) March 22, ... prostate cancer than fertile men according to a new study published in the journal, Cancer., ...
... 22 The Single Party finally bought enough votes to get the Senate-passed healthcare reform through the House, but its victory celebrations ... since "healthcare reform" was first promoted in 1943. , ... , ... ...
... Blue Cross and Blue Shield of Georgia ... bring a regional clinic to Georgia from today, ... Clayton County , Henry County and Spalding County ... based on their financial and vision needs to receive free vision ...
... Across the Country to Make Smart Choices , ... , , ... ... WASHINGTON , March 22 The ...
... were 2.6 times more likely to get more dangerous disease ... risk that a man will develop the aggressive, potentially fatal ... my knowledge, this is the first study to identify a ... Thomas J. Walsh, an assistant professor of urology at the ...
Cached Medicine News:Health News:Brain Function May Drop Quickly Before Alzheimer's 2Health News:Male Infertility Significantly Increases Risk of Prostate Cancer 2Health News:Physicians Urged to Declare Independence from Government, Other Third Parties 2Health News:Physicians Urged to Declare Independence from Government, Other Third Parties 3Health News:Hundreds of Georgia School Children to Receive Free Eye Exams and Glasses 2Health News:Hundreds of Georgia School Children to Receive Free Eye Exams and Glasses 3Health News:Hundreds of Georgia School Children to Receive Free Eye Exams and Glasses 4Health News:Hundreds of Georgia School Children to Receive Free Eye Exams and Glasses 5Health News:National Restaurant Association Says Nutrition Information Provision Is Win for Consumers and Restaurants 2Health News:National Restaurant Association Says Nutrition Information Provision Is Win for Consumers and Restaurants 3Health News:Infertility Raises Risk of More Aggressive Prostate Cancer 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... the new PRONEB® ULTRA compressor. This high ... while delivering more medication to the patient's ... PLUS® or PARI LC STAR® Reusable Nebulizer, ... for inhalation and retention into the lungs. ...
... use with metered dose inhalers., ,ACE ... from MDI canisters. Its versatile design allows ... circuit, in conjunction with an endotracheal airway ... inhalation. ACE may also be used in ...
Medicine Products: